U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}
Status:
Investigational
Source:
NCT00845169: Not Applicable Interventional Completed Endothelial Dysfunction
(2012)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


7-Nitroindazole (aka 7-NI) is an experimental small molecule that acts as a selective inhibitor of neuronal nitric oxide synthase, which normally converts arginine to citrulline and nitric oxide (NO) in neuronal tissues. It has been investigated for potential use as an anti-nociceptive compound and as a means of mitigating neurodegenerative damage.
Status:
US Previously Marketed
Source:
Thiouracil by Lilly
(1946)
Source URL:
First approved in 1946
Source:
Thiouracil by Lilly
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Thiouracil or 2-thiouracil was introduced in 1943 as the first thionamide anti-thyroid drug. Owing to a high frequency of adverse reactions, especially agranulocytosis, use of thiouracil was abandoned in favor of other, less toxic drugs. Thiouracil is not currently used as a thyrostatic drug in humans. Thiouracil inhibits thyroid activity by blocking the enzyme thyroid peroxidase. It is also it is a highly selective inhibitor of neuronal nitric oxide synthase, by interfering with the substrate- and tetrahydrobiopterin (BH(4))-binding to the enzyme. Due to its ability selectively accumulating in de novo-synthesized melanin in overactive melanin-producing cells and thus providing a means to localize melanoma cells, thiouracil can represent a useful new tool to identify modulators of human hair pigmentation.